Sticking to It: Improving outcomes by increasing adherence

Journal of Clinical Oncology

Volumn 34, Issue 21, 2016, Pages 2440-2442

  Hershman, Dawn L ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; COMORBIDITY; DISEASE FREE SURVIVAL; EDITORIAL; HEALTH CARE POLICY; HUMAN; MEDICATION COMPLIANCE; MORTALITY RATE; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84978198934     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.7336     Document Type: Editorial

References (27)

1. Accordino MK, Hershman DL: Disparities and challenges in adherence to oral antineoplastic agents. Am Soc Clin Oncol Ed Book 271-276, 2013
2. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 353: 487-497, 2005
3. Kimmick G, Anderson R, Camacho F, et al: Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27:3445-3451, 2009
4. Neugut AI, Hillyer GC, Kushi LH, et al: Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat 134:419-428, 2012
5. Hershman DL, Kushi LH, Shao T, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128, 2010
6. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003
7. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543-1549, 1996
8. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013
9. Yood MU, Owusu C, Buist DS, et al: Mortality impact of less-thanstandard therapy in older breast cancer patients. J Am Coll Surg 206:66-75, 2008
10. Hsieh KP, Chen LC, Cheung KL, et al: Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women: An Asian population-based study. PLoS One 9:e87027, 2014
11. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 303:1038-1041, 1980
12. Horwitz RI, Horwitz SM: Adherence to treatment and health outcomes. Arch Intern Med 153:1863-1868, 1993
13. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247:1707-1714, 1982
14. Chirgwin JH, Gobbie-Hurder A, Coates AS: Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol 34:2452-2459, 2016
15. Hershman DL, Tsui J, Meyer J, et al: The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst 106:dju319, 2014
16. Partridge AH, Avorn J, Wang PS, et al: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652-661, 2002
17. Neugut A, Zhong Z, Wright J, et al: Nonadherence to medications for chronic conditions and nonadherence to adjuvant hormonal therapy in women with breast cancer. JAMA Oncol 2016 [in press]
18. He W, Fang F, Varnum C, et al: Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. J Clin Oncol 33:2262-2269, 2015
19. Henry NL, Azzouz F, Desta Z, et al: Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936-942, 2012
20. Crew KD, Capodice JL, Greenlee H, et al: Randomized, blinded, shamcontrolled trial of acupuncture for the management of aromatase inhibitorassociated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28:1154-1160, 2010
21. Irwin ML, Cartmel B, Gross CP, et al: Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33:1104-1111, 2015
22. Khan QJ, Reddy PS, Kimler BF, et al: Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119:111-118, 2010
23. Moon JH, Sohn SK, Kim SN, et al: Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol 29: 1179-1185, 2012
24. Jacob L, Hadji P, Albert US, et al: Impact of disease management programs on women with breast cancer in Germany. Breast Cancer Res Treat 153:391-395, 2015
25. Nieuwlaat R, Wilczynski N, Navarro T, et al: Interventions for enhancing medication adherence. Cochrane Database Syst Rev 11:CD000011, 2014
26. Neugut AI, Subar M, Wilde ET, et al: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534-2542, 2011
27. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014